Sector: Life Sciences

Latest content

Generics are the winners as CAFC doubles down on strict Hatch-Waxman venue selection criteria

A decision handed down last Friday against Celgene elaborates on the rules set out in the landmark Valeant case and makes life tough for pharma patent owners

09 November 2021

Patent system should address “blind spot” around AI-generated inventions, KIPO commissioner says

In an exclusive interview with IAM, Kim Yong Rae says innovation will be discouraged if law fails to keep pace with technological change

09 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Biosimilars IP playbook is being re-written by the rise of interchangeables

Landmark designations highlight strategic IP ramifications of automatically-substitutable biosimilars

28 October 2021

Covid-19 patent disputes highlight safe harbour uncertainties for research tool innovators

Allele Therapeutics’ suits against Pfizer and Regeneron could have big implications for the extent to which platforms can monetise IP

26 October 2021

Talks over covid vaccine IP waiver appear increasingly futile

Saturday Opinion: The prospect of an international agreement on the proposed suspension of TRIPS now appears vanishingly small

23 October 2021

Pharma speaks loud and clear on need for 101 changes, but consensus for reform remains elusive

US life sciences leadership is at stake, industry tells USPTO, but comments on eligibility study show deep divisions remain

22 October 2021

Get unlimited access to all IAM content